Goldman Sachs Maintains Sell on Ginkgo Bioworks Holdings, Lowers Price Target to $1.25
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Matthew Sykes maintains a Sell rating on Ginkgo Bioworks Holdings (NYSE:DNA) and lowers the price target from $3 to $1.25.
June 05, 2023 | 12:09 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Goldman Sachs maintains a Sell rating on Ginkgo Bioworks Holdings (NYSE:DNA) and lowers the price target from $3 to $1.25.
The lowered price target by Goldman Sachs analyst Matthew Sykes indicates a bearish outlook on Ginkgo Bioworks Holdings. This news is likely to have a negative impact on the stock price in the short term as it suggests that the stock is overvalued at its current price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100